KTTA•benzinga•May 6, 2025 at 11:06 AM

Pasithea Announces Interim PD Data From Ongoing Phase 1 Trial Of PAS-004 In Advanced Cancer Patients; PAS-004 Shows Up To 91% Inhibition Of pERK, Confirming Substantial Target Engagement

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 6, 2025 by benzinga